Transglutaminase-2 mediates acquisition of neratinib resistance in metastatic breast cancer

Acquisition of resistance to targeted therapies remains a major clinical obstacle for the HER2(+) subtype of breast cancer. Using an isogeneic progression series of HER2(+) breast cancer metastasis we demonstrate that metastatic cells have an increased capacity to acquire resistance to the covalent,...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinde, Aparna, Kulkoyluoglu Cotul, Eylem, Chen, Hao, Smith, Andrew, Libring, Sarah, Solorio, Luis, Wendt, Michael K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213622/
https://www.ncbi.nlm.nih.gov/pubmed/35729402
http://dx.doi.org/10.1186/s43556-022-00079-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213622/
https://www.ncbi.nlm.nih.gov/pubmed/35729402
http://dx.doi.org/10.1186/s43556-022-00079-y

Ejemplares similares